Amgen Reports Phase 2 Data for Baricitinib in Esophageal cancer

Amgen today announced Phase 2 results for baricitinib in patients with esophageal cancer. The study demonstrated that baricitinib reduces biomarker levels compared to standard of care or placebo. These results provide important insights into the treatment of esophageal cancer and support the continued development of baricitinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.